News

Cilofexor plus firocostat well tolerated by patients with fibrosis due to NASH

Cilofexor plus firsocostat for 48 weeks was safe and well tolerated in patients with fibrosis due to nonalcoholic steatohepatitis, according to research presented at The Digital International Liver Congress.“Cilofexor plus firsocostat led to a nonsignificant but higher rate of fibrosis improvement without worsening of NASH and reduced progression to cirrhosis vs. placebo,” Rohit LoombaMD, MHSc,…

News

NUC discontinuation shows durable immune control in e antigen-negative hepatitis B

Discontinuation of long-term nucleos(t)ide analogues has the potential to induce durable immune control and functional cure in patients with e antigen-negative, or HBeAG, chronic hepatitis B, according to a presenter at The Digital International Liver Congress.In his presentation, Florian van Bömmel, from University Hospital Leizig in Germany, said that discontinuing nucleos(t)ide analogues (NUCs) can result…

News

Generic drug substitution laws vary greatly across US

State laws regarding generic drug and interchangeable biologic substitutions vary widely in the United States, researchers reported.Generic drugs saved the U.S. health care system $1.7 trillion between 2007 and 2016, and biologics currently account for 2% of dispensed medications and almost 40% of spending, according to researchers.Past research has linked generic drugs with improved medication…

News

NASH resolves, fibrosis improves in 22% treated with growth factor analogue

Fibroblast growth factor 19 analogue aldafermin showed dose- and duration-dependent reduction in liver fat with resolution of non-alcoholic steatohepatitis in more than one-fifth of cases, according to a presenter at the Digital International Liver Congress.“Ultimately, looking at the study from cohort 4, the primary endpoint was met. Clinically significant improvements in histology regulatory endpoints of…

News

Machine learning outperforms noninvasive tests in NAFLD

Machine learning may be a reasonable solution for screening for fatty liver in the general population in areas where more niche noninvasive tests are unavailable, according to a presenter at the Digital International Liver Congress.“Risk stratification is key to reducing unnecessary testing in liver disease screening. While transient elastography [TE] could be considered the noninvasive…

News

OCA improves non-invasive markers of NASH, advanced fibrosis

Early and sustained improvements in non-invasive markers of nonalcoholic steatohepatitis and advanced fibrosis were observed in patients treated with obeticholic acid, according to research presented at The Digital International Liver Congress.“Improvements over time were generally consistent in patients with stage 2 or 3 fibrosis at baseline,” Jerome Boursier, MD, PhD, from Angers University Hospital in…

News

VIDEO: Younger people with NAFLD, COVID-19 at double risk for mortality

In this exclusive video, Thomas Berg, MD, head of the section of hepatology at The University of Leipzig, discusses data presented at The Digital International Liver Congress on the role of non-alcoholic fatty liver disease in COVID-19 mortality risk.The study found a correlation between obesity and chronic liver disease with mortality in the disease.Although liver…

News

Fatty liver, cirrhosis double mortality risk in COVID-19

Through an international registry presented at the Digital International Liver Congress, experts found COVID-19 in the presence of liver disease like non-alcoholic fatty liver disease or cirrhosis conferred a greater risk for mortality and morbidity.“From everything that was written in the press when it comes to the pandemic, it was clear that comorbidities play a…

News

Fatty acid synthase inhibitor reduces liver fat, markers of liver injury in NASH

TVB-2640, a fatty acid synthase inhibitor, significantly reduced liver fat and serum biomarkers of liver injury, fibrosis and inflammation in patients with nonalcoholic steatohepatitis according to research presented at The Digital International Liver Congress.“Once daily, oral tablet of TVB-2640 appeared to be well-tolerated and had a good safety profile,” Rohit LoombaMD, MHSc, from the division…

News

Genetic variant linked to reduced severe alcoholic hepatitis risk

People who carry a certain genetic variant are at lower risk for developing severe alcoholic hepatitis, according to research presented at The Digital International Liver Congress.Stephen Atkinson, MBBS, PhD, of the department of metabolism, digestion and reproduction at Imperial College London, said that severe alcoholic hepatitis typically occurs in patients with a background of fibrosis…